Costs ‐ not reported · treating upper extremity deficits in individuals with hemiparesis after stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean adverse events: not reported · treating upper extremity deficits in individuals with hemiparesis after stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean upper extremity activity · treating upper extremity deficits in individuals with hemiparesis after stroke
1 finding from 1 review
Mean upper extremity impairment · treating upper extremity deficits in individuals with hemiparesis after stroke
1 finding from 1 review
Activities of daily living · treating upper extremity deficits in individuals with hemiparesis after stroke
1 finding from 1 review
FEV1 % predicted · adults and children with cystic fibrosis
1 finding from 1 review
FEF25-75 · adults and children with cystic fibrosis
1 finding from 1 review
FVC · adults and children with cystic fibrosis
1 finding from 1 review
Sputum: volume · adults and children with cystic fibrosis
1 finding from 1 review
Sputum: weight (dry or wet) (g) · adults and children with cystic fibrosis
1 finding from 1 review
Frequency of exacerbationsb · adults and children with cystic fibrosis
1 finding from 1 review
Participant‐reported satisfaction with treatment intervention · adults and children with cystic fibrosis
1 finding from 1 review
Visual field sensitivity (visual field) · retinitis pigmentosa
1 finding from 1 review
Visual acuitychange in logMAR visual acuity, may be reported as ETDRS · retinitis pigmentosa
It is very uncertain whether vitamin A and fish oils (docosahexaenoic acid) changes visual acuitychange in logMAR visual acuity, may be reported as ETDRS compared with placebo, vitamins (including vitamin A), or no therapy (very low certainty).
1 finding from 1 review
Electroretinography (ERG) · retinitis pigmentosa
1 finding from 1 review
Optical coherence tomography (OCT) · retinitis pigmentosa
1 finding from 1 review
Adverse effects: as reported by studies · retinitis pigmentosa
1 finding from 1 review
Overall survival (baseline risks for low‐ and high‐risk groups in the control arm were estimated at 1 year) · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin showed no clear difference in overall survival (baseline risks for low‐ and high‐risk groups in… compared with cisplatin chemotherapy (high certainty).
1 finding from 1 review
1‐Year survival rate · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin showed no clear difference in 1‐year survival rate compared with cisplatin chemotherapy (high certainty).
1 finding from 1 review
Response rate · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin showed no clear difference in response rate compared with cisplatin chemotherapy (high certainty).
1 finding from 1 review